Thrombin-Hirudin Complex Formation, Thrombin-Antithrombin III Complex Formation, and Thrombin Generation after Intrinsic Activation of Plasma

Summary

To investigate the relative importance of direct inhibition of thrombin by complex formation and of inhibition of thrombin generation to the mechanisms by that unfractionated heparin (UH) and recombinant hirudin (rH) exert their anticoagulant effects, thrombin-antithrombin III complex (TAT) and thrombin-hirudin complex (THC) formation was compared with the generation of thrombin and prothrombin fragments 1 + 2 (F 1 + 2). Clotting was initiated by activation of citrated plasma in the absence or presence of UH or rH using partial thromboplastin, ellagic acid and calcium chloride. THC was determined by means of ELISA using specific antibodies to thrombin and rH.

Activation of citrated plasma resulted in a sudden onset of thrombin generation after a lag phase of 2 min. Addition of 50 ng rH/ml plasma or 0.1 UH/ml plasma prolonged the clotting time to 3 min. While the peak of thrombin was only slightly decreased in hirudinized plasma, in heparinized plasma thrombin generation was significantly lower than in not anticoagulated plasma. This difference was more pronounced when the lag phase was prolonged to 5 min using 400 ng rH/ml plasma or 0.35 U UH/ml plasma. Using 1200 ng rH/ml or 0.65 U UH/ml to obtain a clotting time of 9 min only a small amount of thrombin could be detected in heparinized plasma, but hirudinized plasma still showed a high peak of thrombin. F 1 + 2 showed essentially the same pattern as thrombin. Prior to the onset of visible clot formation in all experiments using different concentrations of UH about the same values of TAT were observed. In contrast, when samples were anticoagulated with different amounts of rH, a dose dependent increase of THC was detected. When calculated from TAT and THC formation, much more thrombin was bound by rH than by AT III.

Our experiments show that after intrinsic activation of plasma UH exerts its anticoagulant effect more by inhibiting thrombin generation, while rH suppresses thrombin generation to a much lesser extent but inhibits clotting more by direct inhibition of thrombin due to the formation of THC.

• References

• 1 Riehl-Bellon N, Carvallo D, Acker M, van Dorsselaer A, Marquet M, Loison G, Lemoine Y, Brown SW, Courtney M, Roitsch C. Purification and biochemical characterization of recombinant hirudin produced by Saccha-romyces cerevisiae. Biochemistry 1989; 28: 2941-2949
• 2 Markwardt F. Hirudin and derivatives as anticoagulant agents. Thromb Haemost 1991; 66: 141-152
• 3 Bichler J, Fritz H. Hirudin, a new therapeutic tool?. Ann Hematol 1991; 63: 67-76
• 4 Marki WE, Wallis RB. The anticoagulant and antithrombotic properties of hirudins. Thromb Haemost 1990; 64: 344-348
• 5 Markwardt F, Hauptmann J, Nowak G, Kleben Ch, Walsmann P. Pharmacological studies on the antithrombotic action of hirudin in experimental animals. Thromb Haemost 1982; 47: 226-229
• 6 Markwardt F, Kaiser B, Nowak G. Studies on antithrombotic effects of recombinant hirudin. Thromb Res 1989; 54: 377-388
• 7 Markwardt F, Nowak G, Stiirzebecher J, GrieBbach U, Walsmann P, Vogel G. Pharmacokinetics and anticoagulant effect of hirudin in man. Thromb Haemost 1984; 52: 160-163
• 8 Ginsberg JS, Hirsh J, Gent M, McKinnon B, Turpi AGG, Levine M, Powers P, Weitz J, Findlen K, Neemeh J, Buller H, Adelman B, Maraga-nore J, Fox I. A phase II study of hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 1992; 86 (Suppl. 01) 409
• 9 Fox I, Dawson A, Loynds P, Eisner J, Findlen K, Levin E, Hanson D, Mant T, Wagner J, Maraganore J. Anticoagulant activity of hirulog^TM a direct thrombin inhibitor, in humans. Thromb Haemost 1993; 69: 157-163
• 10 Parent F, Bridey F, Dreyfus M, Musset D, Grimon G, Duroux P, Meyer D, Simmoneau G. Treatment of severe venous thrombo-embolism with intravenous hirudin (HBW 023): An open pilot study. Thromb Haemost 1993; 70: 386-388
• 11 Griffith MJ. Kinetics of the heparin-enhanced antithrombin III/thrombin reaction. J Biol Chem 1982; 257: 7360-7365
• 12 Lindhout T, Baruch D, Schoen P, Franssen J, Hemker HC. Thrombin generation and inactivation in the presence of antithrombin III and heparin. Biochemistry 1986; 25: 5962-5969
• 13 Barrowcliffe TW, Havercroft SJ, Kemball-Cook G, Lindahl U. The effect of Ca²⁺, phospholipid and factor V on the anti-(factor Xa) activity of heparin and its high-affmity oligosaccharides. Biochem J 1987; 243: 31-37
• 14 Jesty J. Analysis of the generation and inhibition of activated coagulation factor X in pure systems and in human plasma. J Biol Chem 1986; 261: 8695-8702
• 15 Buchanan MR, Boneu B, Ofosu F, Hirsh J. The relative importance of thrombin inhibition and factor Xa inhibition to the antithrombotic effects of heparin. Blood 1985; 65: 198-201
• 16 Pieters J, Lindhout T. The limited importance of factor Xa inhibition to the anticoagulant property of heparin in thromboplastin-activated plasma. Blood 1988; 72: 2048-2052
• 17 Béguin S, Dol F, Hemker HC. Factor IXa inhibition contributes to the heparin effect. Thromb Haemost 1991; 66: 306-309
• 18 Ofosu FA, Sie P, Modi GJ, Fernandez F, Buchanan MR, Blajchman MA, Boneu B, Hirsh J. The inhibition of thrombin-dependent positive-feedback reactions is critical to the expression of the anticoagulant effect of heparin. Biochem J 1987; 243: 579-588
• 19 Ofosu FA, Hirsh J, Esmon CT, Modi GJ, Smith LM, Anvari N, Buchanan MR, Fenton JW, Blajchman MA. Unfractionated heparin inhibits thrombin-catalysed amplification reactions of coagulation more efficiently than those catalysed by factor Xa. Biochem J 1989; 257: 143-150
• 20 Stone SR, Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. Biochemistry 1986; 25: 4622-4628
• 21 Stone SR, Dennis S, Hofsteenge J. Quantitative evaluation of the contribution of ionic interactions to the formation of the thrombin-hirudin complex. Biochemistry 1989; 28: 6857-6863
• 22 Jakubowski JA, Maraganore JM. Inhibition of coagulation and thrombin-induced platelet activities by a synthetic dodecapeptide modeled on the carboxy-terminus of hirudin. Blood 1990; 75: 399-406
• 23 Lindhout T, Blezer R, Hemker HC. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma. Thromb Haemost 1990; 64: 464-468
• 24 Bara L, Bloch MF, Samama MM. A comparative study of recombinant hirudin and standard heparin in the wessler model. Thromb Res 1992; 68: 167-174
• 25 Hemker HC, Willems G, Beguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemost 1986; 56: 9-17
• 26 Bichler J, Sibeck M, Maschler R, Pelzer H, Fritz H. Determination of thrombin-hirudin complex in plasma with an enzyme-linked immunosorbent assay. Blood Coagulation and Fibrinolysis 1991; 2: 129-133
• 27 Béguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemost 1988; 60: 457-462
• 28 McNeely TB, Griffith MJ. The anticoagulant mechanism of action of heparin in contact-activated plasma: Inhibition of factor X activation. Blood 1985; 65: 1226-1231
• 29 Pieters J, Lindhout T, Hemker HC. In situ-generated thrombin is the only enzyme that effectively activates factor VIII and factor V in thromboplastin-activated plasma. Blood 1989; 74: 1021-1024
• 30 Kaiser B, Fareed J, Walenga JM, Hopensteadt D, Markwardt F. In vitro studies on thrombin generation in citrated, r-hirudinized and heparinized whole blood. Thromb Res 1991; 64: 589-596
• 31 Gray E, Watton J, Cesmeli S, Barrowcliffe TW, Thomas DP. Experimental studies on a recombinant hirudin, CGP 39393. Thromb Haemost 1991; 65: 355-359
• 32 Yang XJ, Blajchman MA, Craven S, Smith LM, Anvari N, Ofosu FA. Activation of factor V during intrinsic and extrinsic coagulation. Biochem J 1990; 272: 399-406
• 33 Hemker HC, Wielders S, Kessels H, Béguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993; 70: 617-624